Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide: Clinical and Basic Studies

References

• Wang Z. Y., Chen Z. Differentiation and apoptosis induction therapy in acute promyelocytic leukemia. Lancet Oncol. 2000; 1: 101–106
   PubMedGoogle Scholar
• Chen Z., Tong J. H., Dong S., Zhu J., Wang Z. Y., Chen S. J. Retinoic acid regulatory pathways, chromosomal translocations and acute promyelocyte leukemia. Genes Chromosomes Cancer 1996; 15: 147–156
   PubMed Web of Science ®Google Scholar
• Huang M. E., Ye Y. C., Chen S. R., Chai J. R., Lu J. X., Zhao L., Gu L. J., Wang Z. Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Sun H. D., Ma L., Hu X. C., Zhang T. D. Treatment of acute promyelocytic leukemia by AL-1 therapy. Chin. J. Integral. Chin. Trans. Med. Western Med. 1992; 12: 170–172
   Google Scholar
• Shen Z. X., Chen G. Q., Ni J. H., Li X. S., Xiong S. M., Qiu Q. Y., Zhu J., Tang W., Sun G. L., Yang K. Q., Chen Y., Zhou L., Fang Z. W., Wang Y. T., Ma J., Zhang P., Zhang T. D., Chen S. J., Chen Z., Wang Z. Y. Use of arsenic trioxide (As3O3) in the treatment of acute promyelocytic leukemia (APL): II clinical efficacy and pharmacokinetics in relapsed patients. Blond 1997; 89: 3354–3360
   PubMed Web of Science ®Google Scholar
• Shen Y., Shen Z. X., Yan H., Chen J., Zeng X. Y., Li J. M., Li X. S., Wu W., Xiong S. M., Zhao W. L., Tang W., Wu F., Liu Y. F., Niu C., Wang Z.Y., Chen S. J., Chen Z. Studies on the clinical efficacy and pharmacokinetics of low dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 2001; 15: 735–741
   PubMed Web of Science ®Google Scholar
• Zhang P., Wang S.Y, Hu X. H. Arsenic trioxide-treated 72 cases of acute promyclocytic leukemia. Chin. J. Hematol. 1996; 17: 58–60
   Google Scholar
• Chen G. Q., Zhu J., Shi X. G., Ni J. H., Zhong H. J., Si G. Y., Jin X. L., Tang W., Li X. S., Xiong S. M., Shen Z. X., Sun G. L., Ma J., Zhang P., Zhang T. D., Gazin C., Naoe T., Chen S. J., Wang Z. Y., Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996; 88: 1052–1061
   PubMed Web of Science ®Google Scholar
• Zhang P., Wang S. Y., Hu L. H., Qiu F. Q., Yang H. F., Xiao Y. J., Li X. X., Han X. Y., Zhou J., Liu P. Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide: an analysis of 242 cases. Chin. J. Hematol. 2000; 21: 67–70
   Google Scholar
• Soignet S. L., Frankel S., Tallman M., Douer D., Kantarjian H., Stone R., Sievers E., Kalayeio M., Coutre S., Ellison R., Warrell R. P. Us multicenter trial of arsenic trioxide (AT) in acute promyelocytic leukemia (APL). Blood 1999; 94((suppl. 1))698a
   Google Scholar
• Camacho L. H., Soignet S. L., Chanel S., Ho R., Heller G., Scheinberg D. A., Ellison R., Warrell R.P., Jr. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J. Clin. Oncol. 2000; 18: 2620–2625
   PubMed Web of Science ®Google Scholar
• Soignet S. L., Maslak P., Wang Z. G., Jhanwar S., Calleja E., Dardashti L. J., Corso D., DeBlasio A., Gabrilove J., Scheinbeig D. A., Pandolfi P. P., Warrell R.P., Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 1998; 339: 1341–1348
   PubMed Web of Science ®Google Scholar
• Niu C., Yan H., Yu T., Sun H. P., Liu J. X., Li X. S., Wu W., Zhang F. Q., Chen Y., Zhou L., Li J. M., Zeng X. Y., Yang R. R., Yuan M. M., Ren M. Y., Gu F. Y., Cao Q., Gu B. W., Su X. Y., Chen G. Q., Xiong S. M., Zhang T. D., Waxman S., Wang Z. Y., Chen Z., Hu J., Shen Z. X., Chen S. J. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia. Blood 1999; 94: 3315–3324
   PubMed Web of Science ®Google Scholar
• Lee T. C., Ho I. C. Modulation of cellular antioxidant defense activities by sodium arsenite in human fibroblasts. Arch. Toxicol. 1995; 69: 498–504
   PubMed Web of Science ®Google Scholar
• Barbui T., Finazzi G., Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91: 3093–3102
   PubMed Web of Science ®Google Scholar
• Zhu J., Guo W. M., Yao Y. Y., Zhao W. L., Pan L., Cai X., Ju B., Sun G. L., Wang H. L., Chen S. J., Chen G. Q., Caen J., Chen Z., Wang Z. Y. Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemother-apeutic agents. Leukemia 1999; 13: 1062–1070
   PubMed Web of Science ®Google Scholar
• Chen Z., Brand N. J., Chen A., Chen S. J., Tong J. H., Wang Z. Y., Waxman S., Zelent A. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor α locus due to a variant t(11;17) translocation associated with acute promyelocytic leukemia. EMBO J. 1993; 12: 1161–1167
   PubMed Web of Science ®Google Scholar
• Melnick A., Licht J. D. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93: 3167–3215
   PubMed Web of Science ®Google Scholar
• Chen S. J., Zelent A., Tong J. H., Yu H. Q., Wang Z. Y., Derre J., Berger R., Waxman S., Chen Z. Rearrangement of the retinoic acid receptor alpha and PLZF genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia. J. Clin. Invest. 1993; 91: 2260–2267
   PubMed Web of Science ®Google Scholar
• Sternsdorf T., Puccetti E., Jensen K., Hoelzer D., Will H., Ottmann O. G., Ruthardt M. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol. Cell. Biol. 1999; 19: 5170–5178
   PubMed Web of Science ®Google Scholar
• Redner R. L., Rush E. A., Faas S., Rudert W. A., Corey S. J. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996; 87: 882–886
   PubMed Web of Science ®Google Scholar
• Wells R. A., Catzavelos C., Kamel-Reid S. Fusion of retinoic acid receptor α to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukemia. Nat. Genet. 1997; 17: 109–113
   PubMed Web of Science ®Google Scholar
• Amould C., Philippe C., Bourdon V., Gregoire M. J., Berger R., Jonveaux P. The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor α in acute promyelocytic-like leukemia. Hum. Mol. Genet. 1999; 8: 1741–1749
   PubMed Web of Science ®Google Scholar
• Chen G. Q., Shi X. G., Tang W., Xiong S. M., Zhu J., Cai X., Han Z. G., Ni J. H., Shi G. Y., Jia P. M., Liu M. M., He K. L., Niu C., Ma J., Zhang P., Zhang T. D., Paul P., Naoe T., Kitamura K., Miller W., Waxman S., Wang Z. Y., De The H., Chen S. J., Chen Z. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): LAs2O3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345–3353
   PubMed Web of Science ®Google Scholar
• Zhang T., Westervelt P., Hess J. L. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide. Mod. Pathol. 2000; 13: 954–961
   PubMed Web of Science ®Google Scholar
• Rowan S., Fisher D. E. Mechanisms of apoptotic cell death. Leukemia 1997; 11: 457–465
   PubMed Web of Science ®Google Scholar
• Cai X., Shen Y. L., Zhu Q., Jia P. M., Yu Y., Zhou L., Huang Y., Zhang J. W., Xiong S. M., Chen S. J., Wang Z. Y., Chen Z., Chen G. Q. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000; 14: 262–270
   PubMed Web of Science ®Google Scholar
• Dai J., Weinberg R. S., Waxman S., Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268–277
   PubMed Web of Science ®Google Scholar
• Jing Y., Dai J., Chalmers-Redman R. M., Tatton W. G., Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102–2111
   PubMed Web of Science ®Google Scholar
• Kitamura K., Minami Y., Yamamoto K., Akao Y., Kiyoi H., Saito H., Naoe T. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 2000; 14: 1743–1750
   PubMed Web of Science ®Google Scholar
• Huang C., Ma W. Y., Li J., Dong Z. Arsenic induces apoptosis through a c-Jun NH2 terminal kinase-dependent, p53-independent pathway. Cancer Res. 1999; 59: 3053–3058
   PubMed Web of Science ®Google Scholar
• Li Y. M., Broome J. D. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res. 1999; 59: 776–780
   PubMed Web of Science ®Google Scholar
• Shao W., Fanelli M., Ferrara F. F., Riccioni R., Rosenauer A., Davison K., Lamph W. W., Waxman S., Pelicci P. G., Lo Coco F., Avvisati G., Testa U., Peschle C., Gambacorti-Passerini C., Nervi C., Miller W.H., Jr. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J. Natl. Cancer Inst. 1998; 90: 124–133
   PubMed Web of Science ®Google Scholar
• Gianni M., Koken M. H., Chelbi-Alix M. K., Benoit G., Lanotte M., Chen Z., De The H. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic resistant NB4 cells. Blood 1998; 91: 4300–4310
   PubMed Web of Science ®Google Scholar
• Jing Y., Wang L., Xia L., Chen G. Q., Chen Z., Miller W. H., Waxman S. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 2001; 97: 264–269
   PubMed Web of Science ®Google Scholar
• Lallemand-Breitenbach V., Guillemin M. C., Janin A., Daniel M. T., Dego L., Kogan S. C., Bishop J. M., De The H. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J. Exp. Med. 1999; 189: 1043–1052
   PubMed Web of Science ®Google Scholar